An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone on an online forum asked whether anyone has started a GLP‑1 drug while still dealing with an eating disorder. They reported losing weight at a low dose at first, but still feeling intense cravings and a compulsive need to eat. On a higher dose they felt the urge remain, and travel and calorie-dense food in the U.S. made them feel like they were regaining weight. They described “force feeding” themselves despite the medication and asked if others had the same experience. GLP‑1 drugs (often talked about as “Ozempic” or “Wegovy,” though those are brand names) are medicines that mimic a natural hormone your gut makes after you eat. In plain terms, they usually make people feel less hungry, slow how quickly the stomach empties, and can lead to weight loss for many users. They were developed for diabetes and later used for weight management. But they don’t erase emotions, habits, or all urges to eat; they change some physical signals between the gut, the blood, and the brain. What this post shows is a real-world example, not a clinical trial. It’s one person’s report of mixed results: initial weight loss, persistent urges to binge, and difficulty when exposed to tempting high-calorie foods. That’s consistent with what clinicians and researchers have observed anecdotally and in small studies: GLP‑1s can reduce appetite and binge frequency for some people, but effects vary a lot. Most strong evidence comes from clinical trials that usually exclude people with severe active eating disorders, so there isn’t a large, reliable body of data on how these drugs work for someone actively struggling with binge eating or other disordered-eating behaviors. Why it matters: lots of people with binge-eating or other eating disorders are curious about GLP‑1s because they can reduce appetite and body weight for many users. If someone is hoping a pill will fix compulsive overeating, this shows that it might not be that simple. Emotional drivers, habit patterns, and environmental triggers (like being in a place with very calorie-dense food) can overpower the medication’s effects. For people and their loved ones, it’s important to know that medication may need to be paired with therapy, structured meal plans, and medical supervision—especially if the eating behavior feels out of control. Caveats and risks: GLP‑1 drugs can cause side effects like nausea, diarrhea, constipation, and changes in appetite. Importantly, clinical trials often screen out people with active eating disorders, so safety and effectiveness in that group are not well established. Using them without medical oversight is risky, especially for someone who feels compelled to “force feed” or has other disordered-eating behaviors. If you or someone you know is in this situation, a doctor or eating-disorder specialist should be involved to weigh benefits and harms, adjust treatment, and offer therapy and nutrition support. Regulatory approvals differ by country and by medical condition—don’t assume they’re officially approved for treating eating disorders. Bottom line: GLP‑1 drugs can help curb appetite for many people, but they aren’t a guaranteed fix for binge eating, and they raise special concerns when used by someone with an active eating disorder. Seek medical and mental-health guidance rather than relying on the drug alone.
Source: r/Semaglutide